Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
J Microbiol Immunol Infect ; 52(6): 902-910, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31607575

ABSTRACT

BACKGROUND: Acute respiratory tract infections are commonly caused by viruses in children. The differences in clinical data and outcome between single and multiple viral infections in hospitalized children were analyzed. METHODS: We retrospectively reviewed the medical records of hospitalized children who had fever and a xTAG Respiratory Virus Panel (RVP) test over a 2-year period. The clinical data were analyzed and compared between single and multiple viral infections. Viral etiologies in upper and lower respiratory infections were analyzed and compared. RESULTS: A total of 442 patients were enrolled. Patients with positive viral detection (N = 311) had a significantly lower rate of leukocytosis (p = 0.03), less evidence of bacterial infection (p = 0.004), and shorter duration of hospitalization (p = 0.019) than those with negative viral detection. The age of patients with multiple viral infections was younger than those with single viral infection; however, there were no significant differences in duration of fever, antibiotics treatment and hospitalization between these two groups. The most commonly identified virus was human rhinovirus. About 27% (n = 83) of patients had multiple viral infections. Overall, the highest percentage of human bocavirus infection was detected in multiple viral infections (79%). Lower respiratory tract infection (LRTI) was independently associated with multiple viral infections (p = 0.022), respiratory syncytial virus (RSV) infection (p = 0.001) and longer hospitalization duration (p = 0.011). CONCLUSION: Multiple viral infections were associated with younger age and a higher risk of developing LRTI. However, multiple viral infections did not predict a worse disease outcome. More studies are needed to unveil the interplay between the hosts and different viruses in multiple viral infections.


Subject(s)
Coinfection/virology , Hospitalization/statistics & numerical data , Respiratory Tract Infections/virology , Virus Diseases/diagnosis , Child , Child, Preschool , Coinfection/diagnosis , Electronic Health Records , Female , Fever/virology , Humans , Infant , Male , Respiratory Tract Infections/diagnosis , Retrospective Studies , Viruses/isolation & purification
2.
Sci Rep ; 9(1): 10459, 2019 07 18.
Article in English | MEDLINE | ID: mdl-31320679

ABSTRACT

The treatment of pediatric myocarditis is controversial, and the benefits of intravenous immunoglobulin (IVIG) are inconclusive due to limited data. We searched studies from PubMed, MEDLINE, Embase, and Cochrane Library databases since establishment until October 1st, 2018. Thirteen studies met the inclusion criteria. We included a total of 812 patients with IVIG treatment and 592 patients without IVIG treatment. The meta-analysis showed that the survival rate in the IVIG group was higher than that in the non-IVIG group (odds ratio = 2.133, 95% confidence interval (CI): 1.32-3.43, p = 0.002). There was moderate statistical heterogeneity among the included studies (I2 = 35%, p = 0.102). However, after adjustment using Duval and Tweedie's trim and fill method, the point estimate of the overall effect size was 1.40 (95% CI 0.83, 2.35), which became insignificant. Moreover, the meta-regression revealed that age (coefficient = -0.191, 95% CI (-0.398, 0.015), p = 0.069) and gender (coefficient = 0.347, 95% CI (-7.586, 8.279), p = 0.93) were not significantly related to the survival rate. This meta-analysis showed that IVIG treatment was not associated with better survival. The use of IVIG therapy in acute myocarditis in children cannot be routinely recommended based on current evidence. Further prospective and randomized controlled studies are needed to elucidate the effects of IVIG treatment.


Subject(s)
Immunoglobulins, Intravenous/administration & dosage , Immunologic Factors/administration & dosage , Infant, Newborn, Diseases/drug therapy , Myocarditis/drug therapy , Acute Disease , Child , Humans , Infant , Infant, Newborn , Infant, Newborn, Diseases/pathology , Myocarditis/pathology , Prognosis
3.
J Microbiol Immunol Infect ; 52(2): 352-362, 2019 Apr.
Article in English | MEDLINE | ID: mdl-30177433

ABSTRACT

BACKGROUND/PURPOSE: The health risks of environmental heavy metals have been of concern are well known. The greater likelihood of heavy metal contamination in the physical environment increases the risk of asthma, especially in children. This cross-sectional, population-based study sought to investigate associations between heavy metal exposure and childhood asthma or wheezing. METHODS: Data from 5866 subjects, stratified into age groups of 2-5, 6-11, and 12-15 years, from the National Health and Nutrition Examination Survey 2007-2012 conducted by the Centers for Disease Control and Prevention were analyzed retrospectively. The primary outcome was active asthma. Variables included demographics, anthropometric, and clinical data. Univariate and multivariate logistic regression analyses were used to identify associations between blood heavy metal concentrations and adjusted odds (aORs) of active asthma. RESULTS: Higher concentration of blood lead was associated with higher adjusted odds of having asthma (aOR = 1.08, 95% CI = 1.00-1.16), but no significant effect was shown for current wheezing or whistling. Age-stratified analysis showed that higher blood lead concentration was associated with higher risk for active asthma (aOR = 1.24, 95% CI = 1.08-1.42) and current wheezing or whistling (aOR = 1.19, 95% CI = 1.04-1.38) in the 6-11 years age group, while higher blood mercury concentration was associated with lower risk of current wheezing or whistling (aOR = 0.95, 95% CI = 0.90-0.99). The medium concentration of blood lead was associated with decreased risks of current wheezing or whistling (aOR = 0.54, 95% CI = 0.30-0.96) in the 2-5 years age group. CONCLUSION: Higher concentrations of blood lead are associated with higher odds of asthma in children aged 2-15 years.


Subject(s)
Asthma/epidemiology , Asthma/etiology , Environmental Exposure/adverse effects , Metals, Heavy/toxicity , Adolescent , Child , Child, Preschool , Cross-Sectional Studies , Demography , Environmental Pollution , Female , Humans , Male , Metals, Heavy/blood , Nutrition Surveys , Respiratory Sounds/drug effects , Retrospective Studies , Risk Factors , Socioeconomic Factors , United States
4.
Sci Rep ; 5: 15242, 2015 Oct 16.
Article in English | MEDLINE | ID: mdl-26472621

ABSTRACT

Microscopic haematuria is proposed as a prognostic factor for renal outcomes in patients with glomerulonephritis. However, the role of haematuria in patients with advanced chronic kidney disease (CKD) or heavy proteinuria has not been investigated. We divided 1799 patients with stage 3-5 nondiabetic CKD into 3 groups according to the results from 3 urinalyses: no haematuria (0-2 red blood cells [RBCs]/hpf ≥2 times), mild haematuria (2-5 RBCs/hpf ≥2 times) and moderate haematuria (≥5-10 RBCs/hpf ≥2 times). The estimated glomerular filtration rate was 25.4 mL/min/1.73 m(2), with a urine protein-to-creatinine ratio (UPCR) of 881 mg/g. The hazard ratios (HRs) of mild and moderate haematuria for end-stage renal disease (ESRD) were 1.28 (95% confidence interval [CI]: 1.05-1.56, P = 0.024) and 1.34 (95% CI: 1.03-1.74, P = 0.030), respectively. The HR of moderate haematuria for mortality was 1.56 (95% CI: 1.11-2.20, P = 0.011). According to subgroup analysis, the HR of moderate haematuria for ESRD in patients with a UPCR of <500 mg/g was more prominent than that in patients with a UPCR of ≥500 mg/g. Microscopic haematuria in patients with stage 3-5 nondiabetic CKD is associated with increased risks of ESRD and mortality.


Subject(s)
Hematuria/pathology , Renal Insufficiency, Chronic/pathology , Aged , Aged, 80 and over , Cardiovascular Diseases/etiology , Creatinine/urine , Disease Progression , Erythrocytes/cytology , Female , Follow-Up Studies , Glomerular Filtration Rate , Hematuria/complications , Humans , Logistic Models , Male , Middle Aged , Proportional Hazards Models , Proteins/analysis , Renal Insufficiency, Chronic/complications , Renal Insufficiency, Chronic/mortality , Risk Factors , Severity of Illness Index , Urinalysis
5.
J Immunol ; 185(10): 5828-34, 2010 Nov 15.
Article in English | MEDLINE | ID: mdl-20956337

ABSTRACT

Effective immunotherapy for type 1 diabetes (T1D) relies on active induction of peripheral tolerance. Myeloid-derived suppressor cells (MDSCs) play a critical role in suppressing immune responses in various pathologic settings via multiple mechanisms, including expansion of regulatory T cells (Tregs). In this study, we investigated whether MDSCs could act as APCs to induce expansion of Ag-specific Tregs, suppress T cell proliferation, and prevent autoimmune T1D development. We found that MDSC-mediated expansion of Tregs and T cell suppression required MHC-dependent Ag presentation. A murine T1D model was established in INS-HA/RAG(-/-) mice in which animals received CD4-HA-TCR transgenic T cells via adoptive transfer. We found a significant reduction in the incidence of diabetes in recipients receiving MDSC plus HA, but not OVA peptide, leading to 75% diabetes-free mice among the treated animals. To test further whether MDSCs could prevent diabetes onset in NOD mice, nondiabetic NOD/SCID mice were injected with inflammatory T cells from diabetic NOD mice. MDSCs significantly prevented diabetes onset, and 60% of MDSC-treated mice remained diabetes free. The pancreata of treated mice showed significantly lower levels of lymphocyte infiltration in islet and less insulitis compared with that of the control groups. The protective effects of MDSCs might be mediated by inducing anergy in autoreactive T cells and the development of CD4(+)CD25(+)Foxp3(+) Tregs. Thist study demonstrates a remarkable capacity of transferred MDSCs to downregulate Ag-specific autoimmune responses and prevent diabetes onset, suggesting that MDSCs possess great potential as a novel cell-based tolerogenic therapy in the control of T1D and other autoimmune diseases.


Subject(s)
Diabetes Mellitus, Type 1/immunology , Immunosuppression Therapy , Lymphocyte Activation/immunology , Myeloid Cells/immunology , T-Lymphocytes, Regulatory/immunology , Adoptive Transfer , Animals , Antigen-Presenting Cells/immunology , Cytokines/biosynthesis , Cytokines/immunology , Diabetes Mellitus, Type 1/metabolism , Diabetes Mellitus, Type 1/pathology , Disease Models, Animal , Enzyme-Linked Immunosorbent Assay , Immune Tolerance/immunology , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Inbred NOD , Mice, SCID , Mice, Transgenic , Myeloid Cells/metabolism , Reverse Transcriptase Polymerase Chain Reaction , T-Lymphocytes, Regulatory/cytology , T-Lymphocytes, Regulatory/metabolism
6.
J Agric Food Chem ; 57(18): 8635-42, 2009 Sep 23.
Article in English | MEDLINE | ID: mdl-19678706

ABSTRACT

A significantly higher prevalence of cardiovascular disease (CVD) is reported in patients with systemic lupus erythematosus (SLE) as compared with the general population and accounts for approximately 30% of deaths in SLE patients. However, the mechanism of and treatments for CVD in patients with SLE are still unclear. To explore the effects of taurine on cardiac abnormality in SLE, NZB/W F1 mice were used as the experimental model by receiving control, cholesterol, or cholesterol/taurine diets, respectively. Improved cardiac histopathological changes were observed in left ventricle tissues from the cholesterol/taurine group as compared to the control or cholesterol group. Significant reductions of TUNEL-positive cells, Fas death receptor-related components, mitochondrial-dependent apoptosis, cardiac fibrosis, and fibrotic signaling components were detected in the left ventricle tissues from the cholesterol/taurine group as compared to the control or cholesterol group. Additionally, cardiac IGR1R survival signaling components were significantly increased in the left ventricle tissues from the cholesterol/taurine group as compared to the control or cholesterol group. These findings revealed the protective effects of taurine against the cardiac abnormalities in NZB/W F1 mice and may suggest the potential for clinical application of taurine in treatment of CVD in SLE.


Subject(s)
Cholesterol, Dietary/administration & dosage , Heart Diseases/prevention & control , Lupus Erythematosus, Systemic/complications , Taurine/administration & dosage , Animals , Apoptosis , Diet , Female , Heart Diseases/etiology , Heart Diseases/pathology , In Situ Nick-End Labeling , Mice , Mice, Inbred NZB , Myocardium/pathology
SELECTION OF CITATIONS
SEARCH DETAIL